X-linked Hyphosphatemia Market to reach USD 3.12 Bn by 2032

The global X-linked hypophosphatemia market size is expected to reach USD 1.64 billion in 2025. It is anticipated to touch a valuation of USD 3.12 billion by 2032, displaying a CAGR of 9.6% during the forecast period (2025-2032).  

Increasing awareness of X-linked hypophosphatemia (XLH), advances in targeted therapies, and investments in research and development of new treatments can drive the market growth.

However, the high expenses of drugs like burosumab, regulatory hurdles, and limited awareness in various countries can impede the market growth.

The X-linked hypophosphatemia market is likely to surge due to early screening for XLH in children and the acceptance of aptamers for the treatment of the disease.

The early screening of XLH among children is expected to drive the X-linked hypophosphatemia market growth. Genetic testing of the disease provides accurate results and separates the diagnosis from rickets. The announcement by GeneDX on February 10, 2025, of introducing genetic testing for newborns to identify rare diseases at an early preventive stage is evidence of the massive potential.

Global awareness campaigns by companies can induce demand within the market. For instance, Kyowa Kirin International highlighted the awareness of the disease through an immersive virtual exhibition titled ‘Shine a Light on XLH’ on May 26, 2022.

Aptamer therapies are being approved for the treatment of XLH among children and adults. The precise nature of aptamers for binding itself to specific target sites makes it an ideal choice. They are a part of targeted drug delivery systems and inhibit cancerous growth.

A recent discovery by researchers at Hong Kong Baptist University (HKBU) and Shanghai’s Sixth People’s Hospital discovered an aptamer suitable for treating XLH in December 2024. The Apc001 oligonucleotide aptamer has been developed for inhibiting sclerostin loop 3. This allows bones to grow naturally and restores phosphate levels, while avoiding cardiovascular risks. The Orphan Drug and Pediatric Rare Disease designation by the U.S. FDA can bring new therapeutic options for XLH.

The high treatment costs of burosumab and the financial burden on patients can limit the market growth. The low health coverage of XLH in low-income countries makes it critical for the X-linked hypophosphatemia market to accelerate its drug development. This would make it accessible to patients of all strata and classes, making treatment affordable.

Kyowa Kirin Co., Ltd. shared new research on the efficacy of burosumab for the treatment of XLH at the American Society for Bone and Mineral Research (ASBMR) in September 2024.